Patents by Inventor Ewa M. Grudzien-Nogalska

Ewa M. Grudzien-Nogalska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8153773
    Abstract: New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2?-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 10, 2012
    Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, University of Warsaw
    Inventors: Jacek Jemielity, Ewa M. Grudzien-Nogalska, Joanna Kowalska, Edward Darzynkiewicz, Robert E. Rhoads
  • Publication number: 20100233757
    Abstract: New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2?-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.
    Type: Application
    Filed: June 19, 2008
    Publication date: September 16, 2010
    Applicant: BOARD OF SUPERVISORS OF LOUSIANA STATE UNIVERSITY
    Inventors: Jacek Jemielity, Ewa M. Grudzien-Nogalska, Joanna Kowalska, Edward Darzynkiewicz, Robert E. Rhoads